Truist Financial Corp Lowers Stake in The Clorox Company $CLX

Posted by Andrew Walz on Feb 6th, 2026

Truist Financial Corp cut its holdings in The Clorox Company (NYSE:CLX – Free Report) by 21.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,259 shares of the company’s stock after selling 7,541 shares during the quarter. Truist Financial Corp’s holdings in Clorox were worth $3,361,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Total Investment Management Inc. purchased a new stake in Clorox during the 2nd quarter valued at approximately $25,000. NewSquare Capital LLC increased its holdings in shares of Clorox by 567.6% in the second quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock valued at $27,000 after purchasing an additional 193 shares during the period. True Wealth Design LLC raised its stake in shares of Clorox by 1,020.0% during the third quarter. True Wealth Design LLC now owns 224 shares of the company’s stock worth $28,000 after purchasing an additional 204 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Clorox during the second quarter worth $29,000. Finally, Root Financial Partners LLC purchased a new position in Clorox in the 3rd quarter valued at $29,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Price Performance

CLX stock opened at $117.59 on Friday. The firm has a 50 day moving average of $105.58 and a 200-day moving average of $114.01. The Clorox Company has a 12-month low of $96.66 and a 12-month high of $159.04. The company has a current ratio of 0.74, a quick ratio of 0.50 and a debt-to-equity ratio of 71.03. The company has a market cap of $14.22 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 0.57 and a beta of 0.59.

Clorox (NYSE:CLX – Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.04). The firm had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a net margin of 11.17% and a return on equity of 383.01%. The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the business earned $1.55 earnings per share. As a group, equities analysts expect that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Wednesday, January 28th will be given a $1.24 dividend. The ex-dividend date is Wednesday, January 28th. This represents a $4.96 annualized dividend and a dividend yield of 4.2%. Clorox’s payout ratio is currently 81.05%.

More Clorox News

Here are the key news stories impacting Clorox this week:

Positive Sentiment: Morgan Stanley raised its price target to $136 and kept an “equal weight” rating, highlighting upside vs. the current share level. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
Positive Sentiment: Jefferies trimmed its target to $151 but maintained a “buy” rating, signaling continued conviction in the longer-term upside (large percentage upside remains). Jefferies Adjusts Clorox Price Target to $151
Neutral Sentiment: Clorox will present at the CAGNY conference Feb. 19; management access may provide additional color for investors but is not an immediate earnings driver. Clorox to Present at 2026 CAGNY Conference
Neutral Sentiment: Company is weighing a potential GOJO deal and completing an ERP integration — strategic moves that could boost long-term positioning but are creating near-term execution/cost uncertainty. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
Neutral Sentiment: JPMorgan nudged its target to $117 and kept a neutral rating — a minimal change that signals little near-term conviction from that shop. JPMorgan Adjusts Clorox PT to $117
Neutral Sentiment: TD Cowen raised its target slightly to $111 and maintained a “hold”, a modest signal relative to other shops. TD Cowen Adjusts Clorox Price Target to $111
Negative Sentiment: Brokerage consensus across several shops shows a tilt toward downgrade/reduction in enthusiasm (a published “Reduce” consensus was flagged), which increases selling pressure. The Clorox Company (NYSE:CLX) Given Consensus Rating of “Reduce” by Brokerages
Negative Sentiment: Q2 results were mixed: adjusted EPS missed estimates, organic sales declined year-over-year and management cited ERP/inventory pressures that are squeezing margins. Clorox Q2 Earnings Miss Estimates, Lower Organic Sales Hurt
Negative Sentiment: Analysts warn of a near-term profit squeeze from inventory resets and integration costs, a structural headwind for margins in 2026. Clorox Faces Profit Squeeze From Inventory Reset In 2026
Negative Sentiment: Evercore cut its target to $115 and kept an “underperform” rating, and Deutsche Bank trimmed its target to $112 — additional downward pressure from institutional sellers. Evercore Adjusts Clorox Price Target to $115

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the company’s stock in a transaction on Friday, November 21st. The stock was purchased at an average cost of $104.13 per share, for a total transaction of $416,520.00. Following the acquisition, the director owned 13,000 shares of the company’s stock, valued at $1,353,690. The trade was a 44.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CLX. Wells Fargo & Company upped their price objective on shares of Clorox from $108.00 to $115.00 and gave the stock an “equal weight” rating in a research report on Friday, January 23rd. Jefferies Financial Group cut their price target on shares of Clorox from $152.00 to $151.00 and set a “buy” rating for the company in a report on Wednesday. Evercore ISI lowered their price objective on Clorox from $132.00 to $115.00 and set an “underperform” rating on the stock in a report on Wednesday. TD Cowen increased their target price on Clorox from $108.00 to $111.00 and gave the stock a “hold” rating in a research note on Wednesday. Finally, BNP Paribas Exane reduced their price target on Clorox from $103.00 to $101.00 and set an “underperform” rating for the company in a report on Friday, January 16th. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $117.93.

View Our Latest Research Report on CLX

Clorox Profile

(Free Report)

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.